Restricted accessResearch articleFirst published online 2025-1
Validation of endoplasmic reticulum stress-related gene signature to predict prognosis and immune landscape of patients with non-small cell lung cancer
Lung cancer is one of the most common cancers worldwide, with the incidence increasing each year. It is crucial to improve the prognosis of patients who have lung cancer. Non-Small Cell Lung Cancer (NSCLC) accounts for the majority of lung cancer. Though its prognostic significance in NSCLC has not been often documented, Endoplasmic Reticulum (ER) stress has been identified to be implicated in tumour malignant behaviours and resistance to treatment.
OBJECTIVE:
This work aimed to develop a gene profile linked to ER stress that could be applied to predictive and risk assessment for non-small cell lung cancer.
METHODS:
Data from 1014 NSCLC patients were sourced from The Cancer Genome Atlas (TCGA) database, integrating clinical and Ribonucleic Acid (RNA) information. Diverse analytical techniques were utilized to identify ERS-associated genes associated with patients’ prognoses. These techniques included Kaplan-Meier analysis, univariate Cox regression, Least Absolute Shrinkage and Selection Operator regression analysis (LASSO) regression, and Pearson correlation analysis. Using a risk score model obtained from multivariate Cox analysis, a nomogram was created and validated to classify patients into high- and low-risk groups. The study employed the CIBERSORT algorithm and Single-Sample Gene Set Eenrichment Analysis (ssGSEA) to investigate the tumour immune microenvironment. We used the Genomics of Drug Sensitivity in Cancer (GDSC) database and R tools to identify medicines that could be responsive.
RESULTS:
Four genes – FABP5, C5AR1, CTSL, and LTA4H – were chosen to create the risk model. Overall Survival (OS) was considerably lower ( 0.05) in the high-risk group. When it came to predictive accuracy, the risk model outperformed clinical considerations. Several medication types that are sensitive to high-risk groups were chosen.
CONCLUSION:
Our study has produced a gene signature associated with ER stress that may be employed to forecast the prognosis and therapeutic response of non-small cell lung cancer patients.
ŠutićMVukićABaranašićJFörstiADžuburFSamaržijaM, et al. Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management. J Pers Med.2021 Oct 27; 11(11): 1102.
5.
Lung Cancer Survival Rates 5-Year Survival Rates for Lung Cancer [Internet]. [cited 2023 Mar 22]. Available from: https://www.cancer.org/cancer/lung-cancer/detection-diagnosis-staging/survival-rates.html.
6.
Dagogo-JackIShawAT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol.2018 Feb; 15(2): 81-94.
7.
NegriniSGorgoulisVGHalazonetisTD. Genomic instability – an evolving hallmark of cancer. Nat Rev Mol Cell Biol.2010 Mar; 11(3): 220-8.
8.
HanahanDWeinbergRA. Hallmarks of cancer: The next generation. Cell.2011 Mar 4; 144(5): 646-74.
9.
EberwineJSulJYBartfaiTKimJ. The promise of single-cell sequencing. Nat Methods.2014 Jan; 11(1): 25-7.
10.
SchwarzDSBlowerMD. The endoplasmic reticulum: Structure, function, and response to cellular signaling. Cell Mol Life Sci.2016; 73: 79-94.
11.
CorazzariMGagliardiMFimiaGMPiacentiniM. Endoplasmic reticulum stress, unfolded protein response, and cancer cell fate. Front Oncol.2017; 7: 78.
12.
da SilvaDCValentãoPAndradePBPereiraDM. Endoplasmic reticulum stress signaling in cancer and neurodegenerative disorders: Tools and strategies to understand its complexity. Pharmacol Res.2020 May; 155: 104702.
13.
JooJHLiaoGCollinsJBGrissomSFJettenAM. Farnesol-induced apoptosis in human lung carcinoma cells is coupled to the endoplasmic reticulum stress response. Cancer Res.2007 Aug 15; 67(16): 7929-36.
14.
ThirugnanamTGaletyMGPradhanMRAgarwalRShobanadeviAAlmuftiMSLakshmana KumarR. PIRAP: Medical Cancer Rehabilitation Healthcare Center Data Maintenance Based on IoT-Based Deep Federated Collaborative Learning. International Journal of Cooperative Information Systems.2023 June; 33(10): 2350005.
15.
SongQHawkinsGAWudelLChouPCForbesEPullikuthAK, et al. Dissecting intratumoral myeloid cell plasticity by single-cell RNA-seq. Cancer Med.2019 Jun; 8(6): 3072-85.
16.
LohrMHellwigBEdlundKMattssonJSMBotlingJSchmidtM, et al. Identification of sample annotation errors in gene expression datasets. Arch Toxicol.2015 Dec; 89(12): 2265-72.
17.
BatyFJoergerMFrühMKlingbielDZappaFBrutscheM. 24 h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling. J Transl Med.2017 Mar 30; 15: 66.
18.
BarrettTWilhiteSELedouxPEvangelistaCKimIFTomashevskyM, et al. NCBI GEO: Archive for functional genomics data sets-update. Nucleic Acids Res.2013 Jan; 41(Database issue): D991-995.
19.
ChiccoD. geneExpressionFromGEO: An R Package to Facilitate Data Reading from Gene Expression Omnibus (GEO). Methods Mol Biol.2022; 2401: 187-194.
20.
CloughEBarrettT. The Gene Expression Omnibus Database. Methods Mol Biol.2016; 1418: 93-110.
21.
GoldmanMJCraftBHastieMRepečkaKMcDadeFKamathA, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol.2020 Jun; 38(6): 675-8.
22.
GautierLCopeLBolstadBMIrizarryRA. Affy-analysis of Affymetrix GeneChip data at the probe level. Bioinforma Oxf Engl.2004 Feb 12; 20(3): 307-15.
23.
HaoYHaoSAndersen-NissenEMauckWMZhengSButlerA, et al. Integrated analysis of multimodal single-cell data. Cell.2021 Jun 24; 184(13): 3573-3587.e29.
24.
StelzerGRosenNPlaschkesIZimmermanSTwikMFishilevichS, et al. The GeneCards Suite: From gene data mining to disease genome sequence analyses. Curr Protoc Bioinforma.2016 Jun 20; 54: 1.30.1-1.30.33.
25.
Van de SandeBFlerinCDavieKDe WaegeneerMHulselmansGAibarS, et al. A scalable SCENIC workflow for single-cell gene regulatory network analysis. Nat Protoc.2020 Jul; 15(7): 2247-76.
26.
RitchieMEPhipsonBWuDHuYLawCWShiW, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res.2015 Apr 20; 43(7): e47.
27.
ItoKMurphyD. Application of ggplot2 to Pharmacometric Graphics. CPT Pharmacomet Syst Pharmacol.2013 Oct; 2(10): e79.
28.
GuZEilsRSchlesnerM. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinforma Oxf Engl.2016 Sep 15; 32(18): 2847-9.
29.
AshburnerMBallCABlakeJABotsteinDButlerHCherryJM, et al. Gene Ontology: A tool for the unification of biology. Nat Genet.2000 May; 25(1): 25-9.
30.
KanehisaMFurumichiMTanabeMSatoYMorishimaK. KEGG: New perspectives on genomes, pathways, diseases, and drugs. Nucleic Acids Res.2017 Jan 4; 45(D1): D353-61.
31.
YuGWangLGHanYHeQY. clusterProfiler: An R package for comparing biological themes among gene clusters. Omics J Integr Biol.2012 May; 16(5): 284-7.
32.
EngebretsenSBohlinJ. Statistical predictions with glmnet. Clin Epigenetics.2019 Aug 23; 11: 123.
33.
Saha-ChaudhuriPHeagertyPJ. Non-parametric estimation of a time-dependent predictive accuracy curve. Biostatistics.2013 Jan 1; 14(1): 42-59.
34.
ParkSY. Nomogram: An analogue tool to deliver digital knowledge. J Thorac Cardiovasc Surg.2018 Apr; 155(4): 1793.
35.
FindlayJWADillardRF. Appropriate calibration curve fitting in ligand binding assays. AAPS J.2007 Jun 29; 9(2): E260-267.
36.
VickersAJElkinEB. Decision curve analysis: A novel method for evaluating prediction models. Med Decis Mak Int J Soc Med Decis Mak.2006; 26(6): 565-74.
HänzelmannSCasteloRGuinneyJ. GSVA: Gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics.2013 Jan 16; 14: 7.
39.
YangWSoaresJGreningerPEdelmanEJLightfootHForbesS, et al. Genomics of Drug Sensitivity in Cancer (GDSC): A resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res.2013 Jan; 41(Database issue): D955-961.
40.
GeeleherPCoxNHuangRS. pRRophetic: An R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PloS One.2014; 9(9): e107468.
41.
HuFFLiuCJLiuLLZhangQGuoAY. Expression profile of immune checkpoint genes and their roles in predicting immunotherapy response. Brief Bioinform.2021 May 20; 22(3): bbaa176.
42.
OhCLeeDKongHLeeSWonYJungK, et al. Causes of death among cancer patients in the era of cancer survivorship in Korea: Attention to the suicide and cardiovascular mortality. Cancer Med.2020 Jan 20; 9(5): 1741-52.
43.
ThandraKCBarsoukASaginalaKAluruJSBarsoukA. Epidemiology of lung cancer. Contemp Oncol.2021; 25(1): 45-52.
44.
BillingyNETrompVNMFvan den HurkCJGBecker-CommissarisAWalravenI. Health-related quality of life and survival in metastasized non-small cell lung cancer patients with and without a targetable driver mutation. Cancers.2021 Aug 25; 13(17): 4282.
45.
HechtnerMEichlerMWehlerBBuhlRSebastianMStratmannJ, et al. Quality of life in NSCLC survivors – a multicenter cross-sectional study. J Thorac Oncol.2019 Mar 1; 14(3): 420-35.
46.
QuailDJoyceJ. Microenvironmental regulation of tumor progression and metastasis. Nat Med.2013 Nov; 19(11): 1423-37.
47.
LiuPWeiJMaoFXinZDuanHDuY, et al. Establishment of a prognostic model for hepatocellular carcinoma based on endoplasmic reticulum stress-related gene analysis. Front Oncol.2021; 11: 641487.
48.
XuXTangYZhuJLuoJ. Endoplasmic reticulum stress-related four-biomarker risk classifier for survival evaluation in esophageal cancer. J Oncol.2022; 2022: 5860671.
49.
HuangRLiGWangKWangZZengFHuH, et al. Comprehensive analysis of the clinical and biological significances of endoplasmic reticulum stress in diffuse gliomas. Front Cell Dev Biol.2021; 9: 619396.
50.
Guaita-EsteruelasSGumàJMasanaLBorràsJ. The peritumoural adipose tissue microenvironment and cancer. The roles of fatty acid binding protein 4 and fatty acid binding protein 5. Mol Cell Endocrinol.2018 Feb 15; 462(Pt B): 107-18.
51.
PanLXiaoHLiaoRChenQPengCZhangY, et al. Fatty acid binding protein 5 promotes tumor angiogenesis and activates the IL6/STAT3/VEGFA pathway in hepatocellular carcinoma. Biomed Pharmacother Biomedicine Pharmacother.2018 Oct; 106: 68-76.
52.
WangWChuHJLiangYCHuangJMShangCLTanH, et al. FABP5 correlates with poor prognosis and promotes tumor cell growth and metastasis in cervical cancer. Tumour Biol J Int Soc Oncodevelopmental Biol Med.2016 Nov; 37(11): 14873-83.
53.
YangSKobayashiSSekinoKKagawaYMiyazakiH, ShilS, et al. Fatty acid-binding protein 5 controls lung tumor metastasis by regulating the maturation of natural killer cells in the lung. FEBS Lett.2021 Jul; 595(13): 1797-805.
54.
YousufUSofiSMakhdoomiAMirMA. Identification and analysis of dysregulated fatty acid metabolism genes in breast cancer subtypes. Med Oncol Northwood Lond Engl.2022 Oct 12; 39(12): 256.
55.
LiuJSunBGuoKYangZZhaoYGaoM, et al. Lipid-related FABP5 activation of tumor-associated monocytes fosters immune privilege via PD-L1 expression on Treg cells in hepatocellular carcinoma. Cancer Gene Ther.2022 Dec; 29(12): 1951-60.
56.
PakvisalNKongkavitoonPSathitruangsakCPornpattanarakNBoonsirikamchaiPOuwongprayoonP, et al. Differential expression of immune-regulatory proteins C5AR1, CLEC4A, and NLRP3 on peripheral blood mononuclear cells in early-stage non-small cell lung cancer patients. Sci Rep.2022 Nov 2; 12(1): 18439.
57.
ShenHGuXLiXXiangZZhangRShiF, et al. C5aR1 shapes a non-inflammatory tumor microenvironment and mediates immune evasion in gastric cancer. Bosn J Basic Med Sci. 2022 Dec 10;
58.
QianFXuHZhangYLiLYuR. Methionine deprivation inhibits glioma growth through downregulation of CTSL. Am J Cancer Res.2022; 12(11): 5004-18.
59.
RenTWangSZhangBZhouWWangCZhaoX, et al. LTA4H extensively associates with mRNAs and lncRNAs, indicative of its novel regulatory targets. PeerJ.2023; 11: e14875.
60.
RaverdeauMCunninghamSPHarmonCLynchL. γδ T cells in cancer: A small population of lymphocytes with big implications. Clin Transl Immunol.2019 Oct 10; 8(10): e01080.
61.
Rubraca (Rucaparib) Approved in the US as Monotherapy Treatment for Patients with BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Been Treated with Androgen Receptor-Directed Therapy and a Taxane-Based Chemotherapy [Internet]. 2020 [cited 2023 Mar 27]. Available from: https://www.businesswire.com/news/home/20200515005527/en/Rubraca%C2%AE-Rucaparib-Approved-in-the-U.S.-as-Monotherapy-Treatment-for-Patients-with-BRCA12-Mutant-Metastatic-Castration-Resistant-Prostate-Cancer-mCRPC-Who-Have-Been-Treated-with-Androgen-Receptor-Directed-Therapy-and-a-Taxane-Based-Chemotherapy.
62.
Rubraca (rucaparib) is Approved in the US as a Maintenance Treatment for Recurrent Ovarian Cancer [Internet]. [cited 2023 Mar 27]. Available from: https://www.drugs.com/newdrugs/rubraca-rucaparib-approved-u-s-maintenance-recurrent-ovarian-cancer-4721.html.
63.
FDA Approves Monjuvi (tafasitamab-cxix) in Combination with Lenalidomide for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) Business Wire [Internet]. [cited 2023 Mar 27]. Available from: https://www.businesswire.com/news/home/20200731005497/en/FDA-Approves-Monjuvi%C2%AE-tafasitamab-cxix-Combination-Lenalidomide-Treatment.
64.
FDA Approves REVLIMID (Lenalidomide) In Combination With Rituximab For the Treatment of Adult Patients with Previously Treated Follicular Lymphoma or Marginal Zone Lymphoma [Internet]. 2019 [cited 2023 Mar 27]. Available from: https://www.businesswire.com/news/home/20190528005626/en/FDA-Approves-REVLIMID%C2%AE-Lenalidomide-In-Combination-With-Rituximab-For-the-Treatment-of-Adult-Patients-with-Previously-Treated-Follicular-Lymphoma-or-Marginal-Zone-Lymphoma.
65.
FDA Approves Sutent for Resistant GIST and Kidney Cancer [Internet]. [cited 2023 Mar 27]. Available from: https://www.cancernetwork.com/view/fda-approves-sutent-resistant-gist-and-kidney-cancer.
66.
SUTENT Receives US FDA Approval for Advanced Pancreatic Neuroendocrine Tumors Pfizer [Internet]. [cited 2023 Mar 27]. Available from: https://www.pfizer.com/news/press-release/press-release-detail/sutent_receives_u_s_fda_approval_for_advanced_pancreatic_neuroendocrine_tumors.
67.
ChenXCubillos-RuizJR. Endoplasmic reticulum stress signals in the tumor and its microenvironment. Nat Rev Cancer.2021 Feb; 21(2): 71-88.
